MedPass is the leading full service Medical Device CRO in the EU assisting clients in the quick, efficient and cost effective clinical development and market access of emerging technologies. Our unparalleled regulatory and reimbursement expertise adds value by significantly reducing development timelines.
Europe remains the most attractive location for medical device clinical development, a springboard to access emerging markets in Asia Pacific and South America, and a cost effective location for conducting trials for US FDA.
Our multinational clients appreciate our flexibility, speed and willingness to work on an as needed basis, setting us apart from global CROs. Our start up clients benefit from a single, trusted vendor providing all clinical and regulatory needs from route to market roadmaps to first in man studies, clinical evaluations, Notified Body selection and CE marking, post market clinical follow-up, quality assurance, support during the post-market phase and reimbursement for a seamless development program.
Since 1991, the company has participated in the successful development of hundreds of innovative technologies from the first fully functional cervical disc replacement in the late 1990’s through dedicated interventional stroke and neuroradiology devices to treat stroke in the early 2000’s to the first CE marking of a transcatheter aortic valve. Most recently, MedPass was regulatory consultant and CRO for the first leadless cardiac pacemaker.